Connor, Clark & Lunn Investment Management Ltd. Tg Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$13.32 - $19.19 $1.17 Million - $1.68 Million	-87,699 Reduced 37.74%	144,648 $2.57 Million
Q1 2024 May 09, 2024	SELL	$13.02 - $21.3 $1.48 Million - $2.43 Million	-113,857 Reduced 32.89%	232,347 $3.53 Million
Q4 2023 Feb 09, 2024	BUY	$6.68 - $18.81 $2.31 Million - $6.51 Million	346,204 New	346,204 $5.91 Million
Q2 2023 Aug 10, 2023	BUY	$15.48 - $35.0 $5.07 Million - $11.5 Million	327,606 New	327,606 $8.14 Million
Q3 2021 Nov 12, 2021	SELL	$21.78 - $40.45 $409,790 - $761,066	-18,815 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$32.5 - $48.96 $611,487 - $921,182	18,815 New	18,815 $730,000
Q1 2021 May 13, 2021	SELL	$41.61 - $54.3 $1.02 Million - $1.33 Million	-24,516 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $619,519 - $1.35 Million	24,516 New	24,516 $1.28 Million
Q2 2020 Aug 13, 2020	SELL	$8.9 - $21.84 $356,916 - $875,849	-40,103 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$7.14 - $15.99 $286,335 - $641,246	40,103 New	40,103 $394,000

Others Institutions Holding TGTX

# of Institutions

338

Shares Held

87.6M

Call Options Held

2.35M

Put Options Held

1.7M

Vanguard Group Inc Valley Forge, PA

15.4M
Shares

$447 Million
0.01% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$331 Million
0.0% of portfolio
State Street Corp Boston, MA

9.09M
Shares

$264 Million
0.01% of portfolio
Pictet Asset Management Holding Sa Carouge, V8

3.58M
Shares

$104 Million
0.1% of portfolio
Geode Capital Management, LLC Boston, MA

3.21M
Shares

$93.1 Million
0.01% of portfolio

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.22B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account